LTS Lohmann Therapie-Systeme AG

LTS Lohmann Therapie-Systeme AG, a German-headquartered company in the Pharmaceutical Preparation Manufacturing industry, has not publicly disclosed its carbon emissions data.

However, LTS Lohmann Therapie-Systeme AG has set Science Based Targets initiative (SBTi) approved reduction targets. The company commits to reaching net-zero greenhouse gas emissions across its entire value chain by 2050.

For near-term targets, LTS Lohmann Therapie-Systeme AG aims to reduce absolute Scope 1 and 2 GHG emissions by 50% by 2030, using a 2023 base year. Additionally, the company commits to reducing absolute Scope 3 GHG emissions by 25% within the same timeframe. These Scope 3 reductions cover emissions from purchased goods and services, fuel- and energy-related activities, waste generated in operations, employee commuting, and the end-of-life treatment of sold products.

Looking further ahead, for its long-term targets, the company pledges to reduce absolute Scope 1 and 2 GHG emissions by 90% by 2050, again from a 2023 base year. Similarly, LTS Lohmann Therapie-Systeme AG also commits to reducing absolute Scope 3 GHG emissions by 90% within the same 2050 timeframe.